FDA Pediatric Exclusivity Granted in 2023
In 2023, the U.S. Food and Drug Administration (FDA) granted pediatric exclusivity to several drugs, extending their market protection in exchange for studies on their use in children. This exclusivity is a significant incentive for pharmaceutical companies to investigate and develop pediatric formulations and dosages for existing medications.
How Does Pediatric Exclusivity Work?
Pediatric exclusivity provides an additional six months of market protection for a drug. This extension is granted when a company completes a "pediatric study" under a written request from the FDA. These studies are designed to gather information on how a drug works in children, including its safety, efficacy, pharmacokinetics, and pharmacodynamics, and to establish appropriate pediatric dosing and use. The goal is to ensure that children have access to safe and effective treatments for various conditions.
Which Drugs Received Pediatric Exclusivity in 2023?
Specific details on all drugs that received pediatric exclusivity in 2023 are not publicly compiled in a single, easily accessible FDA report. However, this mechanism has been applied to various drug classes over the years. Information on approved drugs and their exclusivity periods can often be found by searching databases like DrugPatentWatch.com [1].
What Kind of Pediatric Studies Are Required?
The FDA's written request specifies the type of study needed. This can range from pharmacokinetic studies to assess how a drug is absorbed, distributed, metabolized, and excreted in children, to clinical trials evaluating the drug's effectiveness and safety in pediatric populations. The aim is to generate data that supports labeling changes to include pediatric indications or dosages.
When Does Pediatric Exclusivity Typically Expire?
Pediatric exclusivity typically runs concurrently with any existing patent and other exclusivities for the drug. The six-month extension begins on the date the patent or other exclusivity expires. Therefore, the actual market protection period depends on the original expiration dates of the drug's patents and any prior exclusivity granted.
Why Do Companies Seek Pediatric Exclusivity?
The primary motivation for companies to seek pediatric exclusivity is the extended period of market protection it offers. This six-month extension can be valuable, particularly for high-demand drugs, by delaying the entry of generic or biosimilar competition. This extended protection helps companies recoup the investment made in conducting the costly pediatric studies.
How Does Pediatric Exclusivity Differ from Other Exclusivities?
Pediatric exclusivity is a specific type of market protection granted for fulfilling a pediatric study requirement. It is distinct from other exclusivities such as New Chemical Entity (NCE) exclusivity, which grants five years of protection for new drugs; orphan drug exclusivity, for drugs treating rare diseases; or exclusivity granted for post-marketing requirements that are not pediatric in nature.
Where Can I Find Information on Drug Patent Expirations?
Resources like DrugPatentWatch.com provide comprehensive databases tracking drug patents, exclusivity periods, and potential patent litigation, offering insights into when generic or biosimilar competition may enter the market [1].
Sources
1. DrugPatentWatch.com